- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06084624
Evaluation of Topical Rebamipide Versus Topical Betamethasone for Treatment of Oral Aphthous Ulcers
Evaluation of Topical Rebamipide Versus Topical Betamethasone for Treatment of Oral Aphthous Ulcers: A Randomized Clinical Trial
The goal of this randomized clinical trial is to to compare the effect of topical rebamipide to topical betamethasone on pain intensity in patients having recurrent oral aphthous ulcers. The main question it aims to answer is :
What is the effect of topical Rebamipide mouthwash compared to topical betamethasone mouthwash on pain reduction in patients with oral aphthous ulcers?
Participants will will be divided randomly into the two groups and the following outcomes will be measured:
Pain associated with oral ulcers Number of oral ulcers Diameter of oral ulcers Healing time of oral ulcers
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This is a Randomized clinical trial (RCT) parallel groups, two arm, equivalence framework with 1:1 allocation ratio which is based on the hypothesis that topical rebamipide has comparable effect to topical betamethasone on pain intensity in patients having recurrent oral aphthous ulcers.
The participants will be recruited from the pool of the Clinics Medicine, Periodontology and Diagnostic centre, Faculty of Dentistry - Cairo University. The eligible participants will be enrolled in the study in a consecutive order till the sample size is achieved.
Simple randomization will be generated using computerized random number generator (random.org) with allocation ratio (1:1).
Allocation concealment will be done using sequentially numbered sealed opaque containers of the same shape, size and colour until interventions are assigned.
The entire procedure will be explained to the patients and a written consent will be obtained by the operator.
Participants and care givers will be blinded as both topical rebamipide and topical betamethasone mouthwashes will be of same consistency and will be provided in sealed opaque containers of the same shape, size and colour.
The enrolled patients will be divided randomly into two groups. One group will receive topical rebamipide mouthwash four times daily for one week or till healing and the other group will receive topical Corticosteroid (topical betamethasone) four times daily for one week or till healing. The patients will be recalled in the first week (days 3, 5 and 7). The patients will be asked to prohibit use of any topical medication during the trial. Outcome measures will be recorded in each visit.
Data will be analyzed using IBM SPSS advanced statistics (Statistical Package for Social Sciences), version 24 (SPSS Inc., Chicago, IL)
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Mostafa Belal, MSc
- Número de telefone: 01223384483
- E-mail: mostafa.belal@dentistry.cu.edu.eg
Estude backup de contato
- Nome: Sherine Ali, Professor
- Número de telefone: 01280777749
- E-mail: Shereen.Ali@dentistry.cu.edu.eg
Locais de estudo
-
-
-
Cairo, Egito
- Recrutamento
- Faculty of dentistry, Cairo University
-
Contato:
- Mostafa Belal, MSc
- Número de telefone: 01223384483
- E-mail: mostafa.belal@dentistry.cu.edu.eg
-
Contato:
- Sherine Ali, Professor
- Número de telefone: 01280777749
- E-mail: Shereen.Ali@dentistry.cu.edu.eg
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion criteria:
Patients age from 18-70 years old. Patients with active oral ulcers. History of recurrent ulcers in the oral cavity Patients free from any visible oral lesions other than the oral aphthous ulcers.
Patient who will agree to participate in the study and take the supplied interventions.
E8glusion criteria:
- Patients with history of a severe or chronic medical condition including congestive heart failure, malignancy and active infection including tuberculosis, hepatitis and human immunodeficiency virus.
- Patients under immunosuppressive drugs.
- Patients using topical or systemic treatment agents for the oral ulcers
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Rebamipide mouthwash
Rebamipide mouthwash will be administered four times daily for one week or till healing |
Rebamipide (REB), 2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinone-4-yl]-propionic acid, is commonly used in cases of gastric ulcers, gastritis, and dry eye syndrome
Outros nomes:
|
|
Comparador Ativo: Betamethasone mouthwash
Betamethasone mouthwash of will be administered four times daily for one week or till healing |
Betamethasone is a potent glucocorticoid steroid. It is very soluble in water, and therefore it can be used as a mouthwash and has been used for symptomatic relief and treatment of recurrent aphthous ulcers
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pain intensity associated with oral aphthous ulcers
Prazo: During the first week (days 0, 3,5 and 7)
|
pain from oral ulcers will be assessed through visual analogue scale |
During the first week (days 0, 3,5 and 7)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of oral ulcers
Prazo: During the first week (days 0, 3,5 and 7)
|
Number of oral ulcers will be determined through clinical examination |
During the first week (days 0, 3,5 and 7)
|
|
healing time of oral ulcers
Prazo: During the first week (days 0, 3,5, and 7)
|
healing time of oral ulcers will be determined through clinical examination |
During the first week (days 0, 3,5, and 7)
|
|
Diameter of oral ulcers
Prazo: During the first week (days 0, 3,5 and 7),
|
Diameter of oral ulcers will be determined through clinical examination |
During the first week (days 0, 3,5 and 7),
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Publicações Gerais
- Akagi S, Fujiwara T, Nishida M, Okuda A, Nagao Y, Okuda T, Tokuda H, Takayanagi K. The effectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. J Pharm Health Care Sci. 2019 Jul 25;5:16. doi: 10.1186/s40780-019-0146-2. eCollection 2019.
- Kudur MH, Hulmani M. Rebamipide: A Novel Agent in the Treatment of Recurrent Aphthous Ulcer and Behcet's Syndrome. Indian J Dermatol. 2013 Sep;58(5):352-4. doi: 10.4103/0019-5154.117298.
- Matsuda T, Ohno S, Hirohata S, Miyanaga Y, Ujihara H, Inaba G, Nakamura S, Tanaka S, Kogure M, Mizushima Y. Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behcet's disease: a randomised, double-blind, placebo-controlled study. Drugs R D. 2003;4(1):19-28. doi: 10.2165/00126839-200304010-00002.
- Nagai N, Seiriki R, Deguchi S, Otake H, Hiramatsu N, Sasaki H, Yamamoto N. Hydrogel Formulations Incorporating Drug Nanocrystals Enhance the Therapeutic Effect of Rebamipide in a Hamster Model for Oral Mucositis. Pharmaceutics. 2020 Jun 9;12(6):532. doi: 10.3390/pharmaceutics12060532.
- Quijano D, Rodriguez M. [Topical corticosteroids in recurrent aphthous stomatitis. Systematic review]. Acta Otorrinolaringol Esp. 2008 Jun-Jul;59(6):298-307. Spanish.
- Ma Y, Yang M, Sun J, Qu X, Qu Z, Qu W. The effectiveness of lower-level laser therapy on the treatment of minor recurrent aphthous ulcers: a systematic review and meta-analysis. Lasers Med Sci. 2025 Nov 25;40(1):493. doi: 10.1007/s10103-025-04700-8.
- Parra-Moreno FJ, Egido-Moreno S, Schemel-Suarez M, Gonzalez-Navarro B, Estrugo-Devesa A, Lopez-Lopez J. Treatment of recurrent aphtous stomatitis: A systematic review. Med Oral Patol Oral Cir Bucal. 2023 Jan 1;28(1):e87-e98. doi: 10.4317/medoral.25604.
- Rogulj AA, Z Alajbeg I, Brailo V, Skrinjar I, Zuzul I, Vucicevic-Boras V, Alajbeg I. Topical NAVS naphthalan for the treatment of oral lichen planus and recurrent aphthous stomatitis: A double blind, randomized, parallel group study. PLoS One. 2021 Apr 8;16(4):e0249862. doi: 10.1371/journal.pone.0249862. eCollection 2021.
- Manfredini M, Guida S, Giovani M, Lippolis N, Spinas E, Farnetani F, Dattola A, Di Matteo E, Pellacani G, Giannetti L. Recurrent Aphthous Stomatitis: Treatment and Management. Dermatol Pract Concept. 2021 Sep 1;11(4):e2021099. doi: 10.5826/dpc.1104a99. eCollection 2021 Sep.
- Alsahaf S, Alkurdi KA, Challacombe SJ, Tappuni AR. Topical betamethasone and systemic colchicine for treatment of recurrent aphthous stomatitis: a randomised clinical trial. BMC Oral Health. 2023 Oct 3;23(1):709. doi: 10.1186/s12903-023-03335-x.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças bucais
- Doenças estomatognáticas
- Infecções
- Infecções por vírus de RNA
- Doenças Virais
- Infecções por Picornaviridae
- Doenças animais
- Úlcera oral
- Doença de pé e boca
- Compostos policíclicos
- Pregada
- Pregnas
- Esteróides
- Compostos de anel fundido
- Esteróides, fluorados
- Pregadienetriols
- Betametasona
- rebamipide
Outros números de identificação do estudo
- 3623
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .